Efficacy and tolerability of the investigational topical cream SD-101 (6% allantoin) in patients with epidermolysis bullosa: a phase 3, randomized, double-blind, vehicle-controlled trial (ESSENCE study).

ABSTRACT: BACKGROUND:Epidermolysis bullosa (EB) is a rare genetic disorder that manifests as blistering and/or skin erosion. There is no approved treatment for EB; current standard of care consists of wound and pain management. SD-101 6% is a topical cream containing 6% allantoin that was developed for treating skin lesions in patients with EB. The aim of this phase 3, multicenter, randomized, double-blind, vehicle-controlled study was to assess the efficacy and safety of SD-101 6% cream versus vehicle (0% allantoin) on lesions in patients with EB. METHODS:Eligible patients were??1?month old, had a diagnosis of EB (simplex, recessive dystrophic, or intermediate junctional) and a target wound 10-50?cm2 in size that was present for ?21?days. Patients were randomly assigned to SD-101 6% cream or vehicle, which was applied topically once a day to the entire body for 3?months. Primary efficacy endpoints were time to complete target wound closure within 3?months and the proportion of patients who experienced complete target wound closure within 3?months. Post hoc subgroup analyses were conducted by patient age and in those with body surface area index of total body wound burden ?5% at baseline. RESULTS:In total, 169 patients were enrolled and randomly assigned to SD-101 6% (n?=?82) or vehicle (n?=?87). Baseline demographics and disease characteristics were similar between treatment groups. There were no statistically significant differences between treatment groups in time to target wound closure (hazard ratio, 1.004; 95% confidence interval [CI] 0.651, 1.549; P?=?0.985) or proportion of patients with complete target wound closure within 3?months (odds ratio [95% CI], 0.733 [0.365, 1.474]; nominal P?=?0.390). A positive trend toward faster wound closure with SD-101 6% versus vehicle was observed in patients aged 2 to <12?years and those with total body wound burden ?5% at baseline. SD-101 6% cream was well tolerated. CONCLUSIONS:SD-101 6% cream for treatment of EB-associated lesions was not more effective than vehicle in shortening the time to complete target wound closure or achieving complete target wound closure within 3?months. TRIAL REGISTRATION:ClinicalTrials.gov, NCT02384460; Date of trial registration, February 13, 2015; First participant enrolled, March 11, 2015.

SUBMITTER: Paller AS 

PROVIDER: S-EPMC7310548 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature